{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:56:13Z","timestamp":1789250173057,"version":"build-2803163510"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.cca.2021.10.032","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T19:50:45Z","timestamp":1635450645000},"page":"454-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Iron disorders and hepcidin"],"prefix":"10.1016","volume":"523","author":[{"given":"Shilpa","family":"Rana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirmal","family":"Prabhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cca.2021.10.032_b0005","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.tips.2021.05.001","article-title":"Iron metabolism: pathophysiology and pharmacology","volume":"42","author":"Roemhild","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"180","key":"10.1016\/j.cca.2021.10.032_b0010","article-title":"Iron in neurodegeneration \u2013 cause or consequence?","volume":"13","author":"Ndayisaba","year":"2019","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0015","first-page":"51","article-title":"The regulation of iron absorption and homeostasis","volume":"37","author":"Wallace","year":"2016","journal-title":"Clin. Biochem. Rev."},{"key":"10.1016\/j.cca.2021.10.032_b0020","doi-asserted-by":"crossref","first-page":"100872","DOI":"10.1016\/j.mam.2020.100872","article-title":"Regulation of iron homeostasis: lessons from mouse models","volume":"75","author":"Altamura","year":"2020","journal-title":"Mol. Aspects Med."},{"issue":"8","key":"10.1016\/j.cca.2021.10.032_b0025","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2017-05-786590","article-title":"Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin","volume":"131","author":"Aschemeyer","year":"2018","journal-title":"Blood"},{"issue":"7831","key":"10.1016\/j.cca.2021.10.032_b0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41586-020-2668-z","article-title":"Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms","volume":"586","author":"Billesb\u00f8lle","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0035","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3324\/haematol.2019.232124","article-title":"Iron metabolism and iron disorders revisited in the hepcidin era","volume":"105","author":"Camaschella","year":"2020","journal-title":"Haematologica"},{"issue":"5704","key":"10.1016\/j.cca.2021.10.032_b0040","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0045","first-page":"124","article-title":"Hepcidin and its role in iron homeostasis","volume":"20","author":"Kwapisz","year":"2009","journal-title":"EJIFCC"},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0050","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1172\/JCI67225","article-title":"Iron regulation by hepcidin","volume":"123","author":"Zhao","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.bcmd.2007.10.002","article-title":"Regulation of hepcidin: insights from biochemical analyses on human serum samples","volume":"40","author":"Kemna","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0060","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2005-05-2049","article-title":"The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study","volume":"107","author":"Nemeth","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.5045\/br.2013.48.1.10","article-title":"Role of hepcidin in the pathophysiology and diagnosis of anemia","volume":"48","author":"D'angelo","year":"2013","journal-title":"Blood Res."},{"key":"10.1016\/j.cca.2021.10.032_b0070","series-title":"Vitamins and Hormones","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.vh.2019.01.004","article-title":"Chapter Four - Hepcidin and the BMP-SMAD pathway: An unexpected liaison","author":"Silvestri","year":"2019"},{"key":"10.1016\/j.cca.2021.10.032_b0075","doi-asserted-by":"crossref","first-page":"13986","DOI":"10.1038\/srep13986","article-title":"Endofin, a novel BMP-SMAD regulator of the iron-regulatory hormone, hepcidin","volume":"5","author":"Goh","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2021.10.032_b0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cytogfr.2015.11.005","article-title":"Structural insights into BMP receptors: specificity, activation and inhibition","volume":"27","author":"Yadin","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-nutr-071813-105646","article-title":"Bone morphogenetic proteins as regulators of iron metabolism","volume":"34","author":"Parrow","year":"2014","journal-title":"Annu. Rev. Nutr."},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0090","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajh.24888","article-title":"Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6","volume":"92","author":"Canali","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0095","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.3324\/haematol.2019.241984","article-title":"Hemochromatosis proteins are dispensable for the acute hepcidin response to BMP2","volume":"105","author":"Pagani","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.cca.2021.10.032_b0100","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1629","article-title":"High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin","volume":"13","author":"Tanno","year":"2007","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0105","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood-2008-12-195503","article-title":"Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells","volume":"114","author":"Tanno","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.cca.2021.10.032_b0110","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1089\/ars.2013.5819","article-title":"HJV and HFE play distinct roles in regulating hepcidin","volume":"22","author":"Wu","year":"2015","journal-title":"Antioxid. Redox Signal"},{"issue":"44","key":"10.1016\/j.cca.2021.10.032_b0115","doi-asserted-by":"crossref","first-page":"18354","DOI":"10.1074\/jbc.M117.801795","article-title":"Matriptase-2 suppresses hepcidin expression by cleaving multiple components of the hepcidin induction pathway","volume":"292","author":"Wahedi","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0120","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0125","doi-asserted-by":"crossref","first-page":"e0253475","DOI":"10.1371\/journal.pone.0253475","article-title":"Iron overload inhibits BMP\/SMAD and IL-6\/STAT3 signaling to hepcidin in cultured hepatocytes","volume":"16","author":"Charlebois","year":"2021","journal-title":"PLoS ONE"},{"issue":"24","key":"10.1016\/j.cca.2021.10.032_b0130","doi-asserted-by":"crossref","first-page":"10275","DOI":"10.1074\/jbc.M116.770974","article-title":"Interleukin-1\u03b2 (IL-1\u03b2) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein \u03b4 (C\/EBP\u03b4) expression in hepatocytes","volume":"292","author":"Kanamori","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0135","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/intimm\/dxu144","article-title":"Analysis of IL-22 contribution to hepcidin induction and hypoferremia during the response to LPS in vivo","volume":"27","author":"Wallace","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cca.2021.10.032_b0140","doi-asserted-by":"crossref","unstructured":"S. Canali, A. Core, K. Zumbrennen-Bullough, M. Merkulova, C.-Y. Wang, A. Schneyer, A. Pietrangelo, J. Babitt, Activin B induces noncanonical SMAD1\/5\/8 signaling via BMP Type I receptors in hepatocytes: evidence for a role in hepcidin induction by inflammation in male mice, Endocrinology 157 (2016) en20151747.","DOI":"10.1210\/en.2015-1747"},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0145","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.3324\/haematol.2018.202796","article-title":"Hypoxia attenuates inflammation-induced hepcidin synthesis during experimental human endotoxemia","volume":"104","author":"Kiers","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0150","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0155","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1172\/JCI31342","article-title":"Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance","volume":"117","author":"Babitt","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1146\/annurev-nutr-071715-050731","article-title":"Regulation of hepcidin by erythropoiesis: the story so far","volume":"36","author":"Pasricha","year":"2016","journal-title":"Annu. Rev. Nutr."},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0165","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3324\/haematol.2017.187245","article-title":"Circulating iron levels influence the regulation of hepcidin following stimulated erythropoiesis","volume":"103","author":"Mirciov","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2021.10.032_b0170","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exphem.2017.05.002","article-title":"Reciprocal regulation between hepcidin and erythropoiesis and its therapeutic application in erythroid disorders","volume":"52","author":"Wang","year":"2017","journal-title":"Exp. Hematol."},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0175","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.130","article-title":"Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)","volume":"40","author":"Finberg","year":"2008","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0180","first-page":"1321","article-title":"Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies","volume":"35","author":"De Falco","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.cca.2021.10.032_b0185","doi-asserted-by":"crossref","unstructured":"A.E. Donker, R.A. Raymakers, L.T. Vlasveld, T. van Barneveld, R. Terink, N. Dors, P.P. Brons, N.V. Knoers, D.W. Swinkels, Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis, Blood 123(25) (2014) 3873\u201386; quiz 4005.","DOI":"10.1182\/blood-2014-01-548776"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0190","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.3390\/ijms13021497","article-title":"Molecular diagnostic and pathogenesis of hereditary hemochromatosis","volume":"13","author":"Santos","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0195","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2141.2008.07273.x","article-title":"Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels","volume":"142","author":"van Dijk","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0200","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3324\/haematol.2010.033449","article-title":"A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis","volume":"96","author":"Girelli","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0205","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2009-04-216226","article-title":"Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation","volume":"114","author":"Sham","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0210","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00535-010-0259-8","article-title":"Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders","volume":"45","author":"Kaneko","year":"2010","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cca.2021.10.032_b0215","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fphar.2014.00083","article-title":"Iron deficiency in the elderly population, revisited in the hepcidin era","volume":"5","author":"Busti","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.23354","article-title":"Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia","volume":"88","author":"Bregman","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0225","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/art.30623","article-title":"Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia","volume":"63","author":"van Santen","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"23","key":"10.1016\/j.cca.2021.10.032_b0230","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1182\/blood-2015-03-636407","article-title":"Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia","volume":"125","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0235","first-page":"73","article-title":"Serum hepcidin level and rheumatoid arthritis disease activity","volume":"6","author":"Sahebari","year":"2018","journal-title":"Eur. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0240","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/16078454.2020.1738098","article-title":"Expression of serum BMP6 and hepcidin in cancer-related anemia","volume":"25","author":"Cheng","year":"2020","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0245","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/ejh.12402","article-title":"Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis","volume":"94","author":"Shu","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0250","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/jpc.14093","article-title":"Hepcidin in newly diagnosed inflammatory bowel disease in children","volume":"54","author":"Karaskova","year":"2018","journal-title":"J. Paediatr. Child Health"},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0255","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s00134-010-1794-8","article-title":"Diagnostic accuracy of serum hepcidin for iron deficiency in critically ill patients with anemia","volume":"36","author":"Lasocki","year":"2010","journal-title":"Intensive Care Med."},{"issue":"235","key":"10.1016\/j.cca.2021.10.032_b0260","doi-asserted-by":"crossref","first-page":"235re3","DOI":"10.1126\/scitranslmed.3008249","article-title":"Expression of the iron hormone hepcidin distinguishes different types of anemia in African children","volume":"6","author":"Pasricha","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"23","key":"10.1016\/j.cca.2021.10.032_b0265","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1182\/blood-2015-12-639112","article-title":"Hepcidin in the diagnosis of iron disorders","volume":"127","author":"Girelli","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0270","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/s41390-020-1045-9","article-title":"Hepcidin is a relevant iron status indicator in infancy: results from a randomized trial of early vs. delayed cord clamping","volume":"89","author":"Berglund","year":"2021","journal-title":"Pediatr. Res."},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0275","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1039\/C3MT00347G","article-title":"Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells","volume":"6","author":"Kell","year":"2014","journal-title":"Metallomics"},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0280","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1021\/cn5003557","article-title":"Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation","volume":"6","author":"Hare","year":"2015","journal-title":"ACS Chem. Neurosci."},{"issue":"9586","key":"10.1016\/j.cca.2021.10.032_b0285","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0140-6736(07)61235-5","article-title":"Nutritional iron deficiency","volume":"370","author":"Zimmermann","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0290","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1373\/clinchem.2010.149187","article-title":"Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders","volume":"56","author":"Kroot","year":"2010","journal-title":"Clin. Chem."},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0295","doi-asserted-by":"crossref","first-page":"e75518","DOI":"10.1371\/journal.pone.0075518","article-title":"Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform","volume":"8","author":"Laarakkers","year":"2013","journal-title":"PLoS ONE"},{"issue":"40","key":"10.1016\/j.cca.2021.10.032_b0300","doi-asserted-by":"crossref","first-page":"37597","DOI":"10.1074\/jbc.M205305200","article-title":"The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis","volume":"277","author":"Hunter","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.cca.2021.10.032_b0305","first-page":"652","article-title":"Validation of a competitive ELISA assay for the quantification of human serum hepcidin","volume":"75","author":"Dahlfors","year":"2015","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0310","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2014.116723","article-title":"A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis","volume":"100","author":"Patrick","year":"2015","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.cca.2021.10.032_b0315","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood.V128.22.2456.2456","article-title":"Validation of the intrinsic hepcidin IDxTM Test, an LDT for clinical hepcidin assessment","volume":"128","author":"Gutschow","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0320","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jalm\/jfaa038","article-title":"Clinical immunoassay for human hepcidin predicts iron deficiency in first-time blood donors","volume":"5","author":"Gutschow","year":"2020","journal-title":"J. Appl. Lab. Med."},{"issue":"22","key":"10.1016\/j.cca.2021.10.032_b0325","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1182\/blood.V128.22.4820.4820","article-title":"High sensitivity hepcidin-25 bioactive elisas: manual and fully automated system for the quantification of hepcidin-25 in human serum and plasma","volume":"128","author":"Uelker","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0330","doi-asserted-by":"crossref","first-page":"e4581","DOI":"10.1371\/journal.pone.0004581","article-title":"A novel immunological assay for hepcidin quantification in human serum","volume":"4","author":"Koliaraki","year":"2009","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0335","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2008-02-139915","article-title":"Immunoassay for human serum hepcidin","volume":"112","author":"Ganz","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0340","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.fsi.2013.06.005","article-title":"Development of a sandwich ELISA for quantifying hepcidin in Rainbow trout","volume":"35","author":"Santana","year":"2013","journal-title":"Fish Shellfish Immunol."},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0345","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1373\/clinchem.2010.151522","article-title":"A dual-monoclonal sandwich ELISA specific for hepcidin-25","volume":"56","author":"Butterfield","year":"2010","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2021.10.032_b0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aca.2013.08.002","article-title":"Comparison of copper labeling followed by liquid chromatography-inductively coupled plasma mass spectrometry and immunochemical assays for serum hepcidin-25 determination","volume":"799","author":"Konz","year":"2013","journal-title":"Anal. Chim. Acta"},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0355","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1365-2141.2009.07758.x","article-title":"High-sensitive radioimmunoassay for human serum hepcidin","volume":"146","author":"Grebenchtchikov","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0360","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/09674845.2009.11730263","article-title":"Development of a novel immunoassay for the iron regulatory peptide hepcidin","volume":"66","author":"Busbridge","year":"2009","journal-title":"Br. J. Biomed. Sci."},{"key":"10.1016\/j.cca.2021.10.032_b0365","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.euprot.2014.02.004","article-title":"Clinical measurement of Hepcidin-25 in human serum: is quantitative mass spectrometry up to the job?","volume":"3","author":"Delaby","year":"2014","journal-title":"EuPA Open Proteomics"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0370","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4155\/bio-2016-0240","article-title":"Quantification of hepcidin-25 in human cerebrospinal fluid using LC-MS\/MS","volume":"9","author":"Delaby","year":"2017","journal-title":"Bioanalysis"},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0375","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1515\/cclm-2014-1093","article-title":"LC-MS\/MS method for hepcidin-25 measurement in human and mouse serum: clinical and research implications in iron disorders","volume":"53","author":"Lefebvre","year":"2015","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"issue":"20","key":"10.1016\/j.cca.2021.10.032_b0380","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.4155\/bio.13.225","article-title":"Validation of hepcidin quantification in plasma using LC-HRMS and discovery of a new hepcidin isoform","volume":"5","author":"Rochat","year":"2013","journal-title":"Bioanalysis"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0385","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.nano.2015.01.008","article-title":"Hepcidin levels in hyperprolactinemic women monitored by nanopore thin film based assay: correlation with pregnancy-associated hormone prolactin","volume":"11","author":"Wang","year":"2015","journal-title":"Nanomed.: Nanotechnol. Biol. Med."},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0390","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/j.nano.2014.02.005","article-title":"Nanopore film based enrichment and quantification of low abundance hepcidin from human bodily fluids","volume":"10","author":"Fan","year":"2014","journal-title":"Nanomedicine"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0395","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1039\/C0JA00053A","article-title":"Analysis of hepcidin, a key peptide for Fe homeostasis, via sulfur detection by capillary liquid chromatography-inductively coupled plasma mass spectrometry","volume":"26","author":"Konz","year":"2011","journal-title":"J. Anal. At. Spectrom."},{"issue":"19","key":"10.1016\/j.cca.2021.10.032_b0400","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.1021\/ac300578n","article-title":"Elemental labeling and isotope dilution analysis for the quantification of the peptide hepcidin-25 in serum samples by HPLC-ICP-MS","volume":"84","author":"Konz","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2021.10.032_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2021.338863","article-title":"Electrochemical detection of hepcidin based on spiegelmer and MoS2NF-GNR@AuNPs as sensing platform","volume":"1181","author":"Rana","year":"2021","journal-title":"Anal. Chim. Acta"},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0410","doi-asserted-by":"crossref","DOI":"10.1007\/s00604-020-04599-8","article-title":"Gold-silver core-shell nanoparticle\u2013based impedimetric immunosensor for detection of iron homeostasis biomarker hepcidin","volume":"187","author":"Rana","year":"2020","journal-title":"Microchim. Acta"},{"key":"10.1016\/j.cca.2021.10.032_b0415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12951-015-0115-3","article-title":"Surface plasmon resonance based on molecularly imprinted nanoparticles for the picomolar detection of the iron regulating hormone Hepcidin-25","author":"Cenci","year":"2015","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0420","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bios.2012.06.060","article-title":"SPR detection of human hepcidin-25: a critical approach by immuno- and biomimetic-based biosensing","volume":"40","author":"Scarano","year":"2013","journal-title":"Biosens. Bioelectron."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0425","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","article-title":"Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein","volume":"101","author":"Nemeth","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cca.2021.10.032_b0430","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.4155\/bio-2021-0069","article-title":"Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients","volume":"13","author":"Delaby","year":"2021","journal-title":"Bioanalysis"},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0435","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ajh.23289","article-title":"Second round robin for plasma hepcidin methods: first steps toward harmonization","volume":"87","author":"Kroot","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.cca.2021.10.032_b0440","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1039\/C4MT00063C","article-title":"Hepcidin quantification: methods and utility in diagnosis","volume":"6","author":"Konz","year":"2014","journal-title":"Metallomics"},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0445","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1074\/mcp.M800108-MCP200","article-title":"Investigating the quantitative nature of MALDI-TOF MS","volume":"7","author":"Sz\u00e1jli","year":"2008","journal-title":"Mol. Cell. Proteom.: MCP"},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0450","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4155\/bio-2016-0286","article-title":"Measurement of hepcidin isoforms in human serum by liquid chromatography with high resolution mass spectrometry","volume":"9","author":"Handley","year":"2017","journal-title":"Bioanalysis"},{"issue":"50","key":"10.1016\/j.cca.2021.10.032_b0455","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1016\/j.chroma.2011.10.030","article-title":"Development of a nano-liquid chromatography on chip tandem mass spectrometry method for high-sensitivity hepcidin quantitation","volume":"1218","author":"Houbart","year":"2011","journal-title":"J. Chromatogr. A"},{"issue":"9","key":"10.1016\/j.cca.2021.10.032_b0460","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/rcm.4512","article-title":"Quantitation of hepcidin in serum using ultra-high-pressure liquid chromatography and a linear ion trap mass spectrometer","volume":"24","author":"Bansal","year":"2010","journal-title":"Rapid Commun. Mass Spectrometry: RCM"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0465","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1038\/s41598-019-43756-9","article-title":"A targeted mass spectrometric assay for reliable sensitive hepcidin quantification","volume":"9","author":"Moghieb","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2021.10.032_b0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9653747","article-title":"SRM-MS method development for hepcidin-25 peptide","volume":"2018","author":"Cho","year":"2018","journal-title":"J. Anal. Methods Chem."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0475","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ab.2010.08.037","article-title":"Quantification of protein calibrants by amino acid analysis using isotope dilution mass spectrometry","volume":"408","author":"Mu\u00f1oz","year":"2011","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0480","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/vcp.12872","article-title":"Serum hepcidin measurements in healthy dogs using liquid chromatography\/tandem mass spectrometry","volume":"49","author":"Vizi","year":"2020","journal-title":"Vet. Clin. Pathol."},{"key":"10.1016\/j.cca.2021.10.032_b0485","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ab.2016.10.023","article-title":"Whole blood and urine bioactive Hepcidin-25 determination using liquid chromatography mass spectrometry","volume":"517","author":"Swensen","year":"2017","journal-title":"Anal. Biochem."},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0490","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1158\/0008-5472.CAN-14-2465","article-title":"Hepcidin regulation in prostate and its disruption in prostate cancer","volume":"75","author":"Tesfay","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2021.10.032_b0495","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.trac.2012.07.020","article-title":"ICP-MS for absolute quantification of proteins for heteroatom-tagged, targeted proteomics","volume":"40","author":"Sanz-Medel","year":"2012","journal-title":"TrAC, Trends Anal. Chem."},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0500","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1039\/b200072p","article-title":"The use of inorganic elemental standards in the quantification of proteins and biomolecular compounds by inductively coupled plasma spectrometry","volume":"17","author":"Svantesson","year":"2002","journal-title":"J. Anal. At. Spectrom."},{"issue":"8","key":"10.1016\/j.cca.2021.10.032_b0505","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.3390\/ijms19082271","article-title":"Investigations of the copper peptide hepcidin-25 by LC-MS\/MS and NMR","volume":"19","author":"Abbas","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0510","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1515\/cclm-2018-0783","article-title":"Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material","volume":"57","author":"Diepeveen","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0515","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2005-04-1766","article-title":"Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs","volume":"106","author":"Rivera","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cca.2021.10.032_b0520","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1681\/ASN.2015040461","article-title":"Renal handling of circulating and renal-synthesized hepcidin and its protective effects against hemoglobin-mediated kidney injury","volume":"27","author":"van Swelm","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cca.2021.10.032_b0525","doi-asserted-by":"crossref","unstructured":"E. Nemeth, M.S. Tuttle, J. Powelson, M.B. Vaughn, A. Donovan, D.M. Ward, T. Ganz, J. Kaplan, Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization, Science (New York, N.Y.) 306(5704) (2004) 2090\u20133.","DOI":"10.1126\/science.1104742"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0530","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2004-08-3375","article-title":"Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia","volume":"105","author":"Rivera","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cca.2021.10.032_b0535","doi-asserted-by":"crossref","unstructured":"S. Palaneeswari M, M. Ganesh, T. Karthikeyan, A.J.M. Devi, S.V. Mythili, Hepcidin-minireview, J. Clin. Diagn. Res. 7(8) (2013) 1767\u20131771.","DOI":"10.7860\/JCDR\/2013\/6420.3273"},{"issue":"25","key":"10.1016\/j.cca.2021.10.032_b0540","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1182\/blood-2011-02-337907","article-title":"Serum hepcidin: reference ranges and biochemical correlates in the general population","volume":"117","author":"Galesloot","year":"2011","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cca.2021.10.032_b0545","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/jmedgenet-2011-100061","article-title":"Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations","volume":"48","author":"Traglia","year":"2011","journal-title":"J. Med. Genet."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0550","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1373\/clinchem.2016.256768","article-title":"Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material","volume":"62","author":"van der Vorm","year":"2016","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0555","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3324\/haematol.2009.010322","article-title":"Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization","volume":"94","author":"Kroot","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0560","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ab.2009.03.039","article-title":"(Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies","volume":"389","author":"Kroot","year":"2009","journal-title":"Anal. Biochem."},{"issue":"8","key":"10.1016\/j.cca.2021.10.032_b0565","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1373\/clinchem.2012.186866","article-title":"Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration","volume":"58","author":"Troutt","year":"2012","journal-title":"Clin. Chem."},{"issue":"7-8","key":"10.1016\/j.cca.2021.10.032_b0570","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cca.2011.12.015","article-title":"Preanalytical factors and reference intervals for serum hepcidin LC-MS\/MS method","volume":"413","author":"Itkonen","year":"2012","journal-title":"Clinica Chimica Acta; Int. J. Clin. Chem."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0575","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12876-021-01674-z","article-title":"Long-term phlebotomy successfully alleviated hepatic iron accumulation in a ferroportin disease patient with a mutation in SLC40A1: a case report","volume":"21","author":"Nishina","year":"2021","journal-title":"BMC Gastroenterol."},{"issue":"Suppl 1","key":"10.1016\/j.cca.2021.10.032_b0580","first-page":"s84","article-title":"Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis","volume":"1","author":"Sundic","year":"2014","journal-title":"Blood. Transfus."},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0585","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3390\/biology10060546","article-title":"Novel therapeutic advances in \u03b2-thalassemia","volume":"10","author":"Makis","year":"2021","journal-title":"Biology"},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0590","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0595","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000452104","article-title":"Anaemia of chronic disease: an in-depth review","volume":"26","author":"Madu","year":"2017","journal-title":"Med. Principles Practice"},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0600","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2012.075515","article-title":"Iron refractory iron deficiency anemia","volume":"98","author":"De Falco","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0605","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3324\/haematol.2013.084624","article-title":"Manipulation of the hepcidin pathway for therapeutic purposes","volume":"98","author":"Fung","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2021.10.032_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107877","article-title":"Effect of hepcidin antagonists on anemia during inflammatory disorders","volume":"226","author":"Sagar","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0615","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jhep.2010.08.004","article-title":"Hepcidin in human iron disorders: therapeutic implications","volume":"54","author":"Pietrangelo","year":"2011","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0620","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/bjh.17252","article-title":"Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders","volume":"193","author":"Xu","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0625","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/bbb\/zbaa013","article-title":"Generation and characterization of monoclonal antibodies against mature hepcidin and its application to neutralization and quantitative alteration assay","volume":"85","author":"Sakamoto","year":"2021","journal-title":"Biosci. Biotechnol. Biochem."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0630","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-017-0427-x","article-title":"A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia","volume":"10","author":"Vadhan-Raj","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"17","key":"10.1016\/j.cca.2021.10.032_b0635","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0640","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"issue":"21","key":"10.1016\/j.cca.2021.10.032_b0645","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1182\/blood.V118.21.688.688","article-title":"Targeting the hepcidin pathway with RNAi therapeutics for the treatment of anemia","volume":"118","author":"Akinc","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0650","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1359-6446(04)03294-5","article-title":"Lipocalins in drug discovery: From natural ligand-binding proteins to \u2018anticalins\u2019","volume":"10","author":"Schlehuber","year":"2005","journal-title":"Drug Discovery Today"},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0655","doi-asserted-by":"crossref","first-page":"e0212023","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0660","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bph.14143","article-title":"Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey","volume":"175","author":"Hohlbaum","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"23","key":"10.1016\/j.cca.2021.10.032_b0665","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood.V126.23.536.536","volume":"126","author":"Moebius","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0670","doi-asserted-by":"crossref","first-page":"40097","DOI":"10.1038\/srep40097","article-title":"Identification of guanosine 5\u2032-diphosphate as potential iron mobilizer: preventing the hepcidin-ferroportin interaction and modulating the interleukin-6\/stat-3 pathway","volume":"7","author":"Angmo","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0675","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood-2012-09-456756","article-title":"The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys","volume":"121","author":"Schwoebel","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0680","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.13433","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects","volume":"173","author":"Boyce","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"17","key":"10.1016\/j.cca.2021.10.032_b0685","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"van Eijk","year":"2014","journal-title":"Blood"},{"issue":"19 Supplement","key":"10.1016\/j.cca.2021.10.032_b0690","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1158\/1538-7445.AM2014-3847","article-title":"Abstract 3847: The anti-hepcidin Spiegelmer\u00ae Lexaptepid Pegol (NOX-H94) as treatment of anemia of chronic disease in patients with multiple myeloma, low grade lymphoma, and CLL: A phase II pilot study","volume":"74","author":"Georgiev","year":"2014","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0695","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1172\/JCI57693","article-title":"Minihepcidins are rationally designed small peptides that mimic hepcidin activity in mice and may be useful for the treatment of iron overload","volume":"121","author":"Preza","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"18","key":"10.1016\/j.cca.2021.10.032_b0700","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2012-07-440743","article-title":"Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis","volume":"120","author":"Ramos","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0705","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bmcl.2014.12.094","article-title":"Thiol-derivatized minihepcidins retain biological activity","volume":"25","author":"Fung","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.cca.2021.10.032_b0710","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1039\/C6MD00260A","article-title":"Identification of a novel BODIPY minihepcidin tool for the high content analysis of ferroportin (SLC40A1) pharmacology","volume":"7","author":"Skerratt","year":"2016","journal-title":"MedChemComm"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0715","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/biomedicines9020164","article-title":"Pursuing orally bioavailable hepcidin analogues via cyclic N-Methylated mini-hepcidins","volume":"9","author":"Goncalves Monteiro","year":"2021","journal-title":"Biomedicines"},{"issue":"21","key":"10.1016\/j.cca.2021.10.032_b0720","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1016\/j.bmcl.2015.03.012","article-title":"Small cyclic agonists of iron regulatory hormone hepcidin","volume":"25","author":"Chua","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.cca.2021.10.032_b0725","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.V122.21.431.431","article-title":"Treatment with minihepcidin peptide improves anemia and iron overload in a mouse model of thalassemia intermedia","volume":"122","author":"Casu","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0730","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0735","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1053\/j.gastro.2010.07.044","article-title":"BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in hfe knockout mice","volume":"139","author":"Corradini","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0740","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/cvr\/cvv221","article-title":"Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells","volume":"108","author":"Yung","year":"2015","journal-title":"Cardiovasc. Res."},{"issue":"21","key":"10.1016\/j.cca.2021.10.032_b0745","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","article-title":"Deletion of TMPRSS6 attenuates the phenotype in a mouse model of \u03b2-thalassemia","volume":"119","author":"Nai","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0750","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1172\/JCI66969","article-title":"Reducing TMPRSS6 ameliorates hemochromatosis and \u03b2-thalassemia in mice","volume":"123","author":"Guo","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0755","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe\u2212\/\u2212 mice and ameliorates anemia and iron overload in murine \u03b2-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0760","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.23934","article-title":"Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of \u03b2-thalassemia intermedia","volume":"90","author":"Schmidt","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0765","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/cbic.201500651","article-title":"En route to new therapeutic options for iron overload diseases: matriptase-2 as a target for kunitz-type inhibitors","volume":"17","author":"Beckmann","year":"2016","journal-title":"ChemBioChem"},{"key":"10.1016\/j.cca.2021.10.032_b0770","doi-asserted-by":"crossref","unstructured":"X. Li, D.K. Rhee, R. Malhotra, C. Mayeur, L.A. Hurst, E. Ager, G. Shelton, Y. Kramer, D. McCulloh, D. Keefe, K.D. Bloch, D.B. Bloch, R.T. Peterson, Progesterone receptor membrane component-1 regulates hepcidin biosynthesis, J. Clin. Invest. 126(1) (2016) 389\u2013401.","DOI":"10.1172\/JCI83831"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0775","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.bcmd.2014.06.002","article-title":"A chemical screen identifies small molecules that regulate hepcidin expression","volume":"53","author":"Gaun","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0780","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1002\/hep.26490","article-title":"The small molecule, genistein, increases hepcidin expression in human hepatocytes","volume":"58","author":"Zhen","year":"2013","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0785","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2013-07-515957","article-title":"Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras\/RAF and nutrient-dependent mTOR signaling","volume":"123","author":"Mleczko-Sanecka","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0790","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.chembiol.2008.05.011","article-title":"The small-molecule iron transport inhibitor ferristatin\/NSC306711 promotes degradation of the transferrin receptor","volume":"15","author":"Horonchik","year":"2008","journal-title":"Chem. Biol."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0795","doi-asserted-by":"crossref","first-page":"e70199","DOI":"10.1371\/journal.pone.0070199","article-title":"Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo","volume":"8","author":"Byrne","year":"2013","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.cca.2021.10.032_b0800","doi-asserted-by":"crossref","first-page":"G1019","DOI":"10.1152\/ajpgi.00324.2014","article-title":"The small molecule ferristatin II induces hepatic hepcidin expression in vivo and in vitro","volume":"308","author":"Alkhateeb","year":"2015","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0805","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3892\/ijmm.2016.2545","article-title":"Icariin regulates systemic iron metabolism by increasing hepatic hepcidin expression through Stat3 and Smad1\/5\/8 signaling","volume":"37","author":"Zhang","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"18","key":"10.1016\/j.cca.2021.10.032_b0810","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1182\/blood-2011-03-345066","article-title":"Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats","volume":"118","author":"Theurl","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cca.2021.10.032_b0815","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/cb300655w","article-title":"Development of an ALK2-biased BMP type I receptor kinase inhibitor","volume":"8","author":"Mohedas","year":"2013","journal-title":"ACS Chem. Biol."},{"issue":"15 Supplement","key":"10.1016\/j.cca.2021.10.032_b0820","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1158\/1538-7445.AM2015-3647","article-title":"Abstract 3647: Targeting cancer-induced anemia with hepcidin lowering ALK2 inhibitors","volume":"75","author":"Peterson","year":"2015","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0825","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1208\/s12248-015-9770-4","article-title":"Anti-repulsive guidance molecule C (RGMc) antibodies increases serum iron in rats and cynomolgus monkeys by hepcidin downregulation","volume":"17","author":"B\u00f6ser","year":"2015","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0830","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.3324\/haematol.2015.140772","article-title":"Anti-hemojuvelin antibody corrects anemia caused by inappropriately high hepcidin levels","volume":"101","author":"Kovac","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.cca.2021.10.032_b0835","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/imj.15317","article-title":"Unfractionated heparin reduces hepcidin levels in critically ill patients","volume":"51","author":"Vagionas","year":"2021","journal-title":"Int. Med. J."},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0840","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00264-012-1714-3","article-title":"Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity","volume":"37","author":"Brkljacic","year":"2013","journal-title":"Int. Orthop."},{"key":"10.1016\/j.cca.2021.10.032_b0845","doi-asserted-by":"crossref","unstructured":"M. Poli, M. Asperti, P. Ruzzenenti, A. Naggi, P. Arosio, Non-anticoagulant heparins are hepcidin antagonists for the treatment of anemia, Molecules (Basel, Switzerland) 22(4) (2017).","DOI":"10.3390\/molecules22040598"},{"key":"10.1016\/j.cca.2021.10.032_b0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113867","article-title":"Pentosan polysulfate to control hepcidin expression in vitro and in vivo","volume":"175","author":"Asperti","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cca.2021.10.032_b0855","doi-asserted-by":"crossref","unstructured":"M. Poli, M. Asperti, P. Ruzzenenti, A. Naggi, P. Arosio, Non-anticoagulant heparins are hepcidin antagonists for the treatment of anemia, Molecules (Basel, Switzerland) 22(4) (2017) 598.","DOI":"10.3390\/molecules22040598"},{"key":"10.1016\/j.cca.2021.10.032_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173958","article-title":"Low anticoagulant heparin-iron complex targeting inhibition of hepcidin ameliorates anemia of chronic disease in rodents","volume":"897","author":"Li","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.cca.2021.10.032_b0865","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2021.10.032_b0870","doi-asserted-by":"crossref","first-page":"7184760","DOI":"10.1155\/2021\/7184760","article-title":"The effects of dandelion polysaccharides on iron metabolism by regulating hepcidin <i>via<\/i> JAK\/STAT signaling pathway","volume":"2021","author":"Ren","year":"2021","journal-title":"Oxid. Med. Cell. Longevity"},{"issue":"13","key":"10.1016\/j.cca.2021.10.032_b0875","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an Anti\u2013IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.cca.2021.10.032_b0880","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti\u2013IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"issue":"45","key":"10.1016\/j.cca.2021.10.032_b0885","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.3748\/wjg.v17.i45.5032","article-title":"AG490: an inhibitor of hepcidin expression in vivo","volume":"17","author":"Zhang","year":"2011","journal-title":"World J. Gastroenterol.: WJG"},{"issue":"18","key":"10.1016\/j.cca.2021.10.032_b0890","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2021.10.032_b0895","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00109-009-0588-3","article-title":"Natural and synthetic STAT3 inhibitors reduce hepcidin expression in differentiated mouse hepatocytes expressing the active phosphorylated STAT3 form","volume":"88","author":"Fatih","year":"2010","journal-title":"J. Mol. Med. (Berlin, Germany)"},{"key":"10.1016\/j.cca.2021.10.032_b0900","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.freeradbiomed.2021.03.019","article-title":"Black pepper prevents anemia of inflammation by inhibiting hepcidin over-expression through BMP6-SMAD1\/ IL6-STAT3 signaling pathway","volume":"168","author":"Banerjee","year":"2021","journal-title":"Free Radical Biol. Med."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0905","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.4049\/jimmunol.171.7.3863","article-title":"Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells","volume":"171","author":"Bharti","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.cca.2021.10.032_b0910","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood-2018-99-113661","article-title":"Hepcidin is elevated in primary and secondary myelofibrosis and correlates with IL-6 and IL-2R\u03b1 but is high in patients treated with ruxolitinib","volume":"132","author":"Zhou","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0915","first-page":"94","article-title":"Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo","volume":"6","author":"Kandala","year":"2012","journal-title":"Drug Discoveries Therap."},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0920","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/ars.2015.6315","article-title":"Hydrogen sulfide attenuates inflammatory hepcidin by reducing IL-6 secretion and promoting SIRT1-mediated STAT3 deacetylation","volume":"24","author":"Xin","year":"2016","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.cca.2021.10.032_b0925","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2017.10.001","article-title":"Aspirin increases ferroportin 1 expression by inhibiting hepcidin via the JAK\/STAT3 pathway in interleukin 6-treated PC-12 cells","volume":"662","author":"Huang","year":"2018","journal-title":"Neurosci. Lett."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0930","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3945\/jn.113.174201","article-title":"Screening identifies the Chinese medicinal plant caulis spatholobi as an effective HAMP expression inhibitor","volume":"143","author":"Guan","year":"2013","journal-title":"J. Nutrit."},{"issue":"10","key":"10.1016\/j.cca.2021.10.032_b0935","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1089\/jmf.2012.2231","article-title":"Polysaccharide isolated from Angelica sinensis inhibits hepcidin expression in rats with iron deficiency anemia","volume":"15","author":"Liu","year":"2012","journal-title":"J. Med. Food"},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0940","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41390-018-0005-0","article-title":"The interrelationship between hepcidin, vitamin D, and anemia in children with acute infectious disease","volume":"84","author":"Moran-Lev","year":"2018","journal-title":"Pediatr. Res."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0945","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/0148607116678197","article-title":"High-dose vitamin D3 administration is associated with increases in hemoglobin concentrations in mechanically ventilated critically ill adults: a pilot double-blind, randomized, placebo-controlled trial","volume":"42","author":"Smith","year":"2018","journal-title":"J. Parenteral Enteral Nutrit."},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0950","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1681\/ASN.2013040355","article-title":"Suppression of iron-regulatory hepcidin by vitamin D","volume":"25","author":"Bacchetta","year":"2014","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0955","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.clnu.2016.06.015","article-title":"High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults","volume":"36","author":"Smith","year":"2017","journal-title":"Clin. Nutrit."},{"issue":"11","key":"10.1016\/j.cca.2021.10.032_b0960","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/bloodadvances.2018017533","article-title":"Activation of the vitamin D receptor transcription factor stimulates the growth of definitive erythroid progenitors","volume":"2","author":"Barminko","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.cca.2021.10.032_b0965","first-page":"19","article-title":"The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes","volume":"1","author":"Zughaier","year":"2014","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"10.1016\/j.cca.2021.10.032_b0970","doi-asserted-by":"crossref","unstructured":"M. Abdelmoneim Behairy Said, R. Elsharabasy, A. Gharib, M. Zaki, P1375ORAL vitamin c effect on hepcidin level in haemodialysis patients with functional iron deficiency anaemia, Nephrol. Dial. Transpl. 35(Supplement_3) (2020).","DOI":"10.1093\/ndt\/gfaa142.P1375"},{"issue":"3","key":"10.1016\/j.cca.2021.10.032_b0975","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.jrn.2011.09.007","article-title":"Vitamin C affects the expression of hepcidin and erythropoietin receptor in HepG2 cells","volume":"22","author":"Chiu","year":"2012","journal-title":"J. Renal Nutrit.: Off. J. Council Renal Nutrit. Natl. Kidney Found."},{"issue":"7","key":"10.1016\/j.cca.2021.10.032_b0980","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1210\/en.2011-2045","article-title":"17\u03b2-estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site","volume":"153","author":"Yang","year":"2012","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.cca.2021.10.032_b0985","doi-asserted-by":"crossref","first-page":"e0148802","DOI":"10.1371\/journal.pone.0148802","article-title":"Circulating hepcidin-25 is reduced by endogenous estrogen in humans","volume":"11","author":"Lehtihet","year":"2016","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.cca.2021.10.032_b0990","doi-asserted-by":"crossref","first-page":"e1316","DOI":"10.1210\/clinem\/dgz316","article-title":"Testosterone administration during energy deficit suppresses hepcidin and increases iron availability for erythropoiesis","volume":"105","author":"Hennigar","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898121003764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898121003764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:06:01Z","timestamp":1757862361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898121003764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":198,"alternative-id":["S0009898121003764"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2021.10.032","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron disorders and hepcidin","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2021.10.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}